Salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy

Salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy

Background and purpose: CD19-targeting chimeric antigen receptor T-cell (CART) therapy is a promising treatment for relapsed/refractory non-Hodgkin lymphoma, but most patients experience post-CART progression. We describe our institutional experience of salvage radiotherapy (SRT) in this setting. Ma...

Full description

Bibliographic Details
Main Authors: Nikhil Yegya-Raman, Christopher M. Wright, Michael J. LaRiviere, Jonathan A. Baron, Daniel Y. Lee, Daniel J. Landsburg, Jakub Svoboda, Sunita D. Nasta, James N. Gerson, Stefan K. Barta, Elise A. Chong, Stephen J. Schuster, Amit Maity, Andrea Facciabene, Ima Paydar, John P. Plastaras
Format: Article
Language:English
Published: Elsevier 2023-03-01
Series:Clinical and Translational Radiation Oncology
Subjects:
CART therapy
Radiotherapy
Salvage therapy
Non-Hodgkin lymphoma
Relapsed/refractory
Online Access:http://www.sciencedirect.com/science/article/pii/S2405630823000125

Internet

http://www.sciencedirect.com/science/article/pii/S2405630823000125

Similar Items